Isomorphic Labs
AI drug discovery company whose unified drug design engine runs partnered programs with pharmaceutical companies and an internal oncology and immunology pipeline.
Subsidiary of Alphabet (Google)
Company disclosure · 13 Oct 2026Product
Selected offerings — the AI products recorded here, not the vendor's full catalogue.
-
Drug Design Engine Platform
Unified AI system, built on and beyond AlphaFold, that models drug candidates across small molecules and biologics for historically difficult targets. Used internally and through pharma co-development partnerships (e.g. Eli Lilly, Novartis) rather than sold directly.
Closest alternatives 2
Similar products 12
Closest alternatives are pairs a vendor page itself compares. Similar products are matched from what each product does; nothing in that group is asserted as a rivalry.
Sources
- Stage, from total funding
-
$600M external round (2025-03-31, isomorphiclabs.com/articles/isomorphic-labs-announces-600m-external-investment-round) + $2.1B Series B (2026-05-12, this url) = $2.7B, both from the company's own press releases. Neither release states a cumulative total; this is the sum of the two disclosed rounds.
- Founded
-
Wikipedia infobox "founded" field, read 2026-08-27.
- Description
-
Company disclosure · 17 Oct 2026
isomorphiclabs.com/our-tech: "A unified drug design engine for a new era of discovery"; "In addition to our partnered programs, we are also developing an internal drug candidate pipeline focused in oncology and immunology." The old wording said it uses AlphaFold; the page says only that team members contributed to AlphaFold's creation.
Open Isomorphic Labs in the directory
Something wrong here? Send a correction — quote this company id: isomorphic-labs.